Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2003
12/04/2003WO2003099338A2 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
12/04/2003WO2003099337A2 Inclusion complexes of rosiglitazone
12/04/2003WO2003099336A1 Formulation for parenteral administration of sodium channel blockers
12/04/2003WO2003099334A1 Topically applicable pharmaceutical preparation
12/04/2003WO2003099311A1 Chewable compositions containing a gel-forming extract of psyllium
12/04/2003WO2003099288A1 Medicinal composition
12/04/2003WO2003099280A1 Novel formulation for the parenteral application of crobenetine
12/04/2003WO2003099278A1 Ophthalmological use of roflumilast for the treatment of diseases of the eye
12/04/2003WO2003099267A1 Medicament with delayed release of the active substance, containing 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
12/04/2003WO2003099264A1 Compositions and method for transmucosal drug delivery and cryoprotection
12/04/2003WO2003099263A1 At least partially degradable films containing an active ingredient and method for the production thereof
12/04/2003WO2003099262A1 Process for the production of nanoparticles, wherein low mechanical and sonic energies are used simultaneously
12/04/2003WO2003099260A1 Method for preparing polymer micelle pharmaceutical preparation containing drug for injection
12/04/2003WO2003099259A1 Oleaginous oral antiparasitic compositions
12/04/2003WO2003099256A2 FREE-FLOWING, POWDERY COMPOSITION CONTAINING α-LIPONIC ACID (DERIVATIVES)
12/04/2003WO2003099228A2 Compositions and processes for inhibiting gene expression using polynucleotides
12/04/2003WO2003099226A2 Antibody peg positional isomers, compositions comprising same, and use thereof
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099200A2 Composition and method for the treatment of diaper rash using natural products
12/04/2003WO2003099163A1 Vehicles for delivery of biologically active substances
12/04/2003WO2003099007A1 Aqueous fludarabine phosphate composition
12/04/2003WO2003098991A2 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability
12/04/2003WO2003090818A3 Drug-delivery endovascular stent and method for treating restenosis
12/04/2003WO2003088920A3 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics
12/04/2003WO2003080629A3 Phosphorus-containing compounds with polymeric chains, and methods of making and using the same
12/04/2003WO2003075977A3 Agglomerated particles for aerosol drug delivery
12/04/2003WO2003070173A3 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
12/04/2003WO2003069998A8 Stable compositions comprising tezacitabine
12/04/2003WO2003068201A3 High affinity antibody having a tcr-like specificity and use in detection and treatment
12/04/2003WO2003065928A3 Therapeutic polyesters and polyamides
12/04/2003WO2003063823A3 Osmotic delivery system
12/04/2003WO2003063790A3 Additives and products including oligoesters
12/04/2003WO2003061593A3 Novel targeted compositions for diagnostic and therapeutic use
12/04/2003WO2003059263A3 Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions.
12/04/2003WO2003057852A3 Purification and characterization of hla proteins
12/04/2003WO2003057179A3 Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
12/04/2003WO2003057170A3 Oral insulin therapy
12/04/2003WO2003056297A3 Self-assembling polymers, and materials fabricated therefrom
12/04/2003WO2003053465A3 Lyophilized preparation containing antibodies to the egf receptor
12/04/2003WO2003053357A3 Method and related composition employing nanostructures
12/04/2003WO2003045415A3 Self-assembling p53 peptides as gene delivery vehicles
12/04/2003WO2003030878A3 Galenic microparticulate oral formulation
12/04/2003WO2003030867A3 Method for preparing an interactive compound of an anilide derivative with a porous support by supercritical fluid
12/04/2003WO2003026590A3 Biological control of nanoparticles
12/04/2003WO2003025002A3 Method and compositions of defensin-antigen fusion proteins and chemokine-antigen fusion proteins as vaccines for tumors and viral infection
12/04/2003WO2003022217A3 Treatment of excessive radiation (e.g. sunburn) exposure
12/04/2003WO2003017991A3 Injection solution containing a dihydropyridin derivative
12/04/2003WO2003017941A3 Flexible applicator for applying oil-in-water emulsion with improved stability
12/04/2003WO2003015748A3 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
12/04/2003WO2003001876A3 T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
12/04/2003WO2002086134A3 Buffer solution for electroporation and a method comprising the use of the same
12/04/2003WO2002083626A3 Alkyl and/or alkenyl glycerol carbamates
12/04/2003WO2002078747A8 Pregabalin lactose conjugates
12/04/2003WO2002074344A3 Peg-conjugates of hgt-nk4
12/04/2003WO2002074193A3 METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
12/04/2003WO2002058694A3 Method of treating hematologic tumors and cancers using beta lapachone
12/04/2003WO2002043774A3 Compositions and therapeutical use of polynucleotides encoding tcrs
12/04/2003WO2002012241A8 Compounds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated diseases or dysfunction
12/04/2003US20030226155 Modified transferrin-antibody fusion proteins
12/04/2003US20030225450 Drug-delivery endovascular stent and method for treating restenosis
12/04/2003US20030225394 Comprises sodium chloride, sesame oils, essential oils, peppermint oils, and eucalyptus oil in syringe
12/04/2003US20030225309 Radioactive compositions and methods of use thereof
12/04/2003US20030225300 Compounds and compositions for delivering active agents
12/04/2003US20030225254 Comprises monoclonal antibody for treating and prevention of tumor progression; antitumor agents
12/04/2003US20030225163 Sulfonamide derivatives
12/04/2003US20030225148 Biological methods of use of 4-amino-3-mercapto-triazoles
12/04/2003US20030225144 Anticoagulants, methyl (2R,3R)-2-(3-(amino(imino)methyl)benzyl)-3-((4-(1-oxido-4-pyridinyl) benzoyl)amino)butanoate; therapeutic treatment of cardiovascular disorders
12/04/2003US20030225137 2-pyridinyl)-methyl)sulfinyl)-1H-benzimidazole derivatives
12/04/2003US20030225136 Heterocyclic imines such as (5)6-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H -benzimidazole and salts, used as antisecretory agents
12/04/2003US20030225135 Dry-blend pharmaceutical formulations
12/04/2003US20030225104 Pharmaceutical compositions for poorly soluble drugs
12/04/2003US20030225089 Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
12/04/2003US20030225066 Peritoneal dialysis solution with taurolidine
12/04/2003US20030225039 Method of treatment using bisphosphonic acid
12/04/2003US20030225033 Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof
12/04/2003US20030225032 Pharmaceutical composition
12/04/2003US20030225031 Liquid or gel solution for nasal administration also containing a permeation-enhancement agent for transmucosal drug uptake.
12/04/2003US20030225000 Parathyroid hormone; stabilizer, especially a polyol stabilizer; buffer to maintain the pH at 3-7; and water
12/04/2003US20030224974 Compositions for delivery of therapeutics and other materials, and methods of making and using the same
12/04/2003US20030224971 Manufacture of polyglutamate-therapeutic agent conjugates
12/04/2003US20030224522 Methods for delivering nucleic acid molecules into cells and assessment thereof
12/04/2003US20030224447 For preparation of immunogens, antibodies and conjugates, for use in competitive immunoassays for the detection of ketamine ((+-)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone) and its primary metabolite, norketamine
12/04/2003US20030224063 Boron nitride particles coated with a silicone compound, and a fragrance molecularly entrapped within a cyclodextrin compound.
12/04/2003US20030224059 Drug microparticles
12/04/2003US20030224055 Compositions and processes for inhibiting gene expression using polynucleotides
12/04/2003US20030224053 Mixture of a polymer, an active ingredient and a solvent capable of being preserved within a container such that on release forms a peelable, water removable, agent-releasing film on the surface of skin
12/04/2003US20030224052 Water soluble proteins (especially hair) and covalent interprotein crosslinks other than disulfide crosslinks.
12/04/2003US20030224051 Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
12/04/2003US20030224050 Drug delivery system for sustained delivery of glipizide
12/04/2003US20030224043 Increasing the bioavailability of low solubility drugs, including a disintegrant and a porosigen promoting disintegrate in less than 10 minutes; high speed, drug delivery
12/04/2003US20030224041 Emulsion formulations for hydrophilic active agents
12/04/2003US20030224039 Infusing at a low temperature below the phase transition of lipid; use for intravenous administration, inhalation administration; no toxic solvents, simple process; bactericides
12/04/2003US20030224038 Cross-linkable phosphonate-containing supramolecular complexes and their use for delivery of therapeutic and diagnostic agents
12/04/2003US20030224037 An antitumor agent oxaliplatin in transferrins liposome ligand and polyoxyethylene glycol, improving the storage stability, detoxifying and inhibiting the side effect caused by therapeutic drug
12/04/2003US20030224035 A topical or transdermal drug delivery, including an inorganic hydroxide to neutralize the acids, increase the flux of the active agent through a body surface, increase the permeability
12/04/2003US20030224032 A substrate having a vapor deposited furanone compounds, covalent bonding through etherification or amination; protective coatings on medical equipment, seeds, fibrics, wool, hair, silk, cotton, chitin, collagen, animal
12/04/2003US20030224021 Methods of using epitope peptides of human pathogens
12/04/2003US20030224006 A solid phase that is sustained by intermolecular interactions (hydrogen bonding) between two or more independent molecular entities, and at least one entity is a drug; improved drug solublity, stability, bioavailability
12/04/2003US20030224002 Administering to a patient having a disorder associtaed with an intracellular pathogen, a molecular conjugate of a photosensitizer and a targeting moiety, wherein the targeting moiety targets conjugate to the pathogen or infected cell
12/04/2003US20030224000 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
1 ... 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 ... 1712